In 2023, in response to a set of proposed telemedicine rules, DEA received more than 38,000 comments and held two days of public listening sessions. In light of that feedback and discussion, and to give DEA time to consider a new path forward for telemedicine, DEA and the Department of...

DEA received more than 38,000 comments on its proposed telemedicine rules and recently held two days of public listening sessions related to those rules. We continue to carefully consider the input received and are working to promulgate a final set of telemedicine regulations by the fall of 2024, giving patients...

On August 1, 2023, the Drug Enforcement Administration (DEA) and U.S. Food and Drug Administration (FDA) issued a joint letter updating the public on the ongoing prescription stimulant shortages impacting patients across the United States and actions to resolve these shortages. The DEA and FDA are committed to working together...